Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Clinical Study of Dual Specificity CD19 and CD22 Chimeric Antigen Receptor T Cell Therapy in Relapsed or Refractory Lymphoma

Next Previous
Trial Profile

A Phase I Clinical Study of Dual Specificity CD19 and CD22 Chimeric Antigen Receptor T Cell Therapy in Relapsed or Refractory Lymphoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LCAR L10D (Primary)
  • Indications B-cell lymphoma
  • Focus Adverse reactions

    • Most Recent Events

    • 03 Mar 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 18 Feb 2018 to 10 Mar 2019.
    • 10 Feb 2019 Planned number of patients changed from 12 to 9.
    • 10 Feb 2019 Planned initiation date changed from 18 Sep 2018 to 18 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top